In this setting, ILC2s partially antagonized the IL-33 dependent, NK cell-mediated anti-tumor response, as evidenced by cell depleting experiments in which the lack of ILC2 CD73+ cells led to enhanced NK cell activity and better tumor control (92). Here, NT5E is linked to neoplasm.